reCross Cardio develops transcatheter septal occluders designed to treat atrial septal defects and patent foramen ovale, minimizing the need for open-heart surgery. Their devices provide a less invasive option for patients, reducing recovery time and associated healthcare costs.
Funding
$4.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Atrial septal defects (ASDs) and patent foramen ovale (PFO) are congenital heart defects that can lead to serious health complications if left untreated. Traditional treatment methods often involve invasive open-heart surgery, which carries significant risks and requires lengthy recovery periods. There is a need for less invasive solutions that can effectively close these defects while minimizing patient trauma and recovery time.
Solution
reCross Cardio develops transcatheter septal occluders designed to provide a minimally invasive alternative to open-heart surgery for treating ASDs and PFOs. Their devices are designed to be delivered through a catheter, allowing for precise placement and closure of the defect without the need for a large incision. This approach aims to reduce patient recovery time, minimize the risk of complications, and lower associated healthcare costs compared to traditional surgical methods. The occluders are engineered to promote tissue ingrowth, ensuring long-term closure and stability.
Target Audience
The primary target audience includes interventional cardiologists and hospitals specializing in the treatment of congenital heart defects, as well as patients with ASDs and PFOs seeking less invasive treatment options.
Features
- Catheter-delivered septal occluders for minimally invasive ASD and PFO closure
- Designed to reduce recovery time and minimize complications compared to open-heart surgery
- Engineered for precise placement and secure closure of septal defects
- Promotes tissue ingrowth for long-term stability and effectiveness